Apolipoprotein B and apolipopotein A-I in vascular risk prediction – a review

Current Pharmaceutical Design

Volumn 20, Issue 40, 2014, Pages 6289-6298

  Schmidt, C ^a   Bergstrom G ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

ApoB apoA I ratio; Apolipoprotein B; Intima media thickness; Myocardial infarction; Peripheral atherosclerosis; Plaque; Stroke

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL, LDL;

APOLIPOPROTEIN A1 APOLIPROTEIN B RATIO; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CORONARY RISK; FEMORAL ARTERY; GROUPS BY AGE; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC PARAMETERS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; BLOOD; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; RISK FACTORS;

EID: 84930824710     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140620121828     Document Type: Article

References (50)

1. [1] Ladich E, Virmani R, Burke A. Sudden cardiac death not related to coronary atherosclerosis. Toxicologic Pathology 2006; 34: 52-7
2. [2] Olofsson S-O, Wiklund O, Borén J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Management 2007; 3: 491-502
3. [3] Carnevale Schianca GP, Pedrazzoli R, Onolfo S, et al. ApoB/apoAI is better that LDL-C in detecting cardiovascular risk. Nutr Metbol Cardiovasc Dis 2011; 21: 406-11
4. [4] Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, mew risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence. J Int Med 2006; 259: 493-519
5. [5] Sniderman AD, Furberg CD, Keech A, et al. Apoliporpteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777-80
6. [6] Simon A, Chironi G, Garipey J, Del Pino M, Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherogenesis in asymptomatic men. Atherosclerosis 2005; 179: 339-44
7. [7] Elovson J, Chatterton JE, Bell GT, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988; 29: 1461-73
8. [8] Walldius G, Jungner I. The apoB/apoA-I ratio: a strong new risk factor for cardiovascular disease and target for lipid-lowering therapy – a review of the evidence. J Int Med 2006; 259: 493-519
9. [9] Walldius G. The apoB/apoA-I ratio is a strong predictor of cardiovascular risk. Lipoproteins – role in health and diseases. In Frank S, Kostner G, Eds. Biochemistry, genetics and molecular biology. Intech. 2012.
10. [10] Huang F, Yang Z, Xu B, et al. Both serum apolipoprotein B and apolipoprotein B/apolipoprotein A-I ratio are associated with carotid intima-media thickness. PLOS One 2013; 1(8): e54628
11. [11] Gardener H, Della Morte D, Elkind MSV, Sacco RL, Rundek T. Lipids and carotid plaques in the northern Manhattan study (NOMAS). BMC Cardiovasc Dis 2009; 9: 55.
12. [12] Panayito A, Griffin M, Georgiou N, et al. ApoB/apoA-I ratio and subclinical atherosclerosis. Int Angiol 2008; 1: 74-80
13. [13] Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3-years in middle-aged men. Stroke 2004; 22: 2248-52
14. [14] Schmidt C, Wikstrand J. High apoB/apoA-I ratio is associated with increased progression rate of carotid artery intima-media thickness in clinically healthy 58-year-old men: Experiences from very longterm follow-up in the AIR study. Atherosclerosis 2009; 205: 284-9
15. [15] Jadhav UM, Kadam NN. Apolipoproteins: correlation with carotid intima-media thickness and coronary artery disease. J Assoc Physician India 2004; 52: 370-5
16. [16] McQueen MJ, Hawken S, Wang X, et al. Lipid, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372: 224-33
17. Castelli WP. Epidemiology of coronary heart disease: the Framingham study Am J Cardiol 1984; 76: 4-12
18. [17] Walldius G, Jungner I Holme I, Aastveit AH, Kolar W, Steiner E. High aplipoprotein B, loe apoliporpotein A-I, and improvment in the prediciton of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33
19. [18] Parish S, Peto R, Palmer A, et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009; 30; 2137-46
20. [19] Benn M, Nordestgaard BG, Boje Jensen G, Tybjærg-Hansen A. Improving prediction of ischemic cardiovasular disease in the general population using apoB. The Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 2007; 27: 661-70
21. [20] Sierra-Johnson J, Fisher RM, Romero-Corral A, et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 2009; 30: 710-7
22. [21] Chien KL, Hsu HC, Su TS, Chen MF, Lee YT, Hu FB. Apolipoprotein B and non-hig density lipoprotein cholesterol and the risk of coronary heart disease in Chinese. J Lipid Res 2007; 48: 2499-505
23. [22] Ingelsson E, Schefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298: 776-85
24. [23] Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005; 26: 271-8
25. [24] Talmud PJ, Hawe E, Miller GJ, Humphries SE. Non fasting apolipoprotein B and triglycerides levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002; 22: 1918-23
26. [25] van der Steeg WA, Boekholdt M, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007; 146: 640-8
27. [26] Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. Circulation 1996; 94: 273-8
28. [27] Kim HK, Chang SA, Choi EK, et al. Association between plasma lipids, and apolipoproteins and coronary artery disease: a crosssectional study in a low-risk Korean population. Int J Cardiol 2005; 101: 435-40
29. [28] Schmidt C, Bergström G. Apo B/apoA-I ratio and apoB: long-term predictors for myocardial infarction in initially healthy middle aged men-a 13-year follow-up. Angiology 2013; nov 25 In press
30. [29] Agaston-Coldea L, Zdrenhea D, Pop D, Crciun A, Rusu ML, Mocan T. Apolipoproteins A-I and B-markers in coronary risk evaluation. Rom J Intern Med 2007; 45: 251-8
31. [30] Agaston-Coldea L, Mocan T, Gatfossé M, Dumitrascu DL. The correlation of apolipoprotein B, apolipoprotein B/apolipoprotein AI ratio and lipoprotein(a) with myocardial infarction. Centr Eur J Med 2008; 3: 422-9
32. [31] Goswami B, Rajappa M, Mallika V, Kumar S, Shukla DK. ApoB/apoA-I ratio: a better discriminator of coronary artery disease risk than other conventional lipid ratios in Indian patients with acute myocardial infarction. Acta Cardiol 2008; 63: 749-55
33. [32] Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371: 1612-23
34. [33] Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB7apoA-I ratio: results of the AMORIS prospective study. J Int Med 2006; 259: 259-66
35. [34] O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010; 376: 112-3
36. [35] Kostapanos MS, Christogiannis Bika E, Bairaktari ET, Goudevenos JA, Elisaf MS, Milionis HJ. Apolipoprotein B-to-A1 ratio as a predictorof acute ischemic nonembolic stroke in elderly subjects. J Stroke Cerebrovasc Dis 2010; 19(6): 497-502
37. [36] White C. Intermittent claudication. N Engl J Med 2007; 356: 1241-50
38. [37] Johansson L, Schmidt C. Increased apoB/apoA-I ratio is predictive of peripheral arterial disease in initially healthy 58-year-old men during 8.9 years of follow-up. Angiology 2009; 60(5): 539-45
39. [38] Pilger E, Pristautz H, Pfeiffer KH, Kostner G. retrospective evaluation of risk factors for peripheral atherosclerosis by stepwise discriminant analysis. Atherosclerosis 1983; 3: 57-63
40. [39] Schmidt C, Fagerberg B. ApoB/apoA-I ratio is related to femoral artery plaques also in 64-year-old women also in cases with low LDL cholesterol. Atherosclerosis 2008; 196: 817-22
41. [40] Schmidt C, Fagerberg B, Wikstrand J, Hulthe J. ApoB/apoA-I ratio is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men. Atherosclerosis 2006; 189: 178-85
42. [41] Williams K, Tchernhof A, Hunt KJ, Wagenknecht LE, Haffner SM, Sniderman AD. Diabetes, abdominal adiposity, and atherogenic dyslipoproteinemia in women compared with men. Diabetes 2008; 57: 3289-96
43. [42] Leiviskä J, Sundvall J, Alfthan G, Jauhiainen M, Salomaa V. Apolipoprotein AI, apolipoprotein B and apolipoproteinB/ apolipoprotein A-I ratio: reference intervals compared with values in different pathophysiological conditions from the FINRISK 2007 study. Clinica Chimica Acta 2011; 412: 1146-50
44. [43] Sattar N, Williams K, Sniderman AD, D’Agostino R, Haffner SM. Comparison of the associations of apolipoprotein B and nonhigh-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin ResistanceATherosclerosis Study. Circulation 2004; 110: 2687-93
45. [44] Park JH, Hong KS, Lee EJ, Lee J, Kim DE. Hogh levels of apolipoproteinB/ A-I ratio are associated with intracranial atherosclerotic stenosis. Stroke 2011; 42: 3040-6
46. [45] Munther P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for cotonary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: 9-17
47. [46] Shishehbor MH, Oliviera LPJ, Luer MS, et al. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol 2008; 101: 1741-6
48. [47] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
49. [48] The Task Force for the management of dyslipidaemia of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32: 1769-818
50. [49] The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000